

Cipla launches Ciposcillo® – A next-generation oscillometer device for respiratory diagnostics

- Designed for early and accurate diagnosis of Obstructive airway disease such as COPD, and Asthma
- Suitable for elderly, pediatric, and effort-limited patients
- Further advances Cipla's commitment to transforming respiratory health through advanced diagnostics

Mumbai, May 6, 2026: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as "Cipla" today announced the launch of Ciposcillo®, an advanced oscillometer designed for accurate and precise assessment of respiratory mechanics. The device enables early diagnosis of obstructive airway diseases such as Chronic Obstructive Pulmonary Disease (COPD) and Asthma. Built on US FDA cleared technology and engineered for Indian clinical practice, Ciposcillo® is CDSCO approved and ISO certified.

With respiratory diseases on the rise in India, early detection and diagnosis of lung health conditions remains critical. Ciposcillo® combines precision, portability and clinically validated technology to better enable clinicians to assess patients across diverse healthcare settings. Importantly, the oscillometer can assess respiratory functions using normal, tidal breathing, eliminating the need for forceful patient effort. This makes it particularly suitable for use in elderly patients, young children, and others who may not be able to perform effort-dependent tests such as spirometry. Ciposcillo® incorporates India-specific reference values and is supported by Z-score-based interpretation for more individualized assessments, with a user-friendly interface for easy, seamless use.

Speaking on the launch, **Achin Gupta, MD and Global CEO**, Cipla said, "At Cipla, innovation is central to how we address patient needs across the healthcare continuum – from therapies to diagnostics. With Ciposcillo®, we are not only bringing advanced diagnostic technology closer to clinicians to empower better decision-making, but also enabling a simpler, effort-independent approach that makes it accessible across age groups and care settings. This is another step in our journey to improving lung health outcomes and delivering on our purpose of Caring for Life."

Ciposcillo® expands Cipla's diagnostic toolkit available to physicians, reinforcing the company's broader commitment to advancing disease detection and management, especially in high-burden areas such as respiratory health.

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ * MAT February 2026 dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Dec'25), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT Nov'25), and 3rd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Dec'25). For nine decades, making a difference to patients has inspired

every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

Media Contacts:**Corporate Communications**

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Diksha Maheshwari

E-Mail: Investor.Relations@cipla.com

Disclaimer: The Information is not intended to serve as medical advice nor is it to be construed as a substitute for medical opinion given by a Registered Medical Practitioner. Kindly consult a qualified doctor (Registered Medical Practitioner) before starting any treatment/ medicine & for definitive diagnosis.